Pharmacometrics and Systems Biology in Oncology: Is There an Intersection?

Pharmacometrics and Systems Biology in Oncology: Is There an Intersection?

International Journal of Clinical Pharmacology and Therapeutics, Vol. 51 – No. 1/2013 (89-90) Pharmacometrics and systems biology in oncology: Is there an intersection? Charlotte Kloft Extended Abstract Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie ©2013 Dustri-Verlag Dr. K. Feistle Universitaet Berlin, Berlin, Germany ISSN 0946-1965 DOI 10.5414/CPP51089 e-pub: December 21, 2012 Key words Background cine, mathematics and statistics: Pharmaco- pharmacometrics kinetic/pharmacodynamic/biomarker/disease – systems biology – Oncology involves a therapeutic area with monoclonal antibodies modeling aims to elucidate the mechanism- – biomarkers – systems complex and individual disease states and dis- based relationships between dosing – drug pharmacology ease progression and there is a limited num- exposure – resulting drug effects while incor- ber of anticancer drugs available. The drugs porating knowledge of the patients and their are usually administered in empirical com- disease [1]. plex dosing regimens which result in highly Systems biology aims from a bottom-up variable success rates. The following two ap- approach to model important system prop- proaches to achieve a more streamlined and erties to understand the complex pathways, rational drug development and drug treatment networks and regulatory and feedback mech- seem appealing: anisms on different spatial and temporal lev- 1. More sophisticated understanding of els [2]. the patient’s health/disease state and disease Due to their attractive characteristics (e.g. progression (“system”). high specificity to target, i.e., binding (only) 2. Development of new drugs with defined to specific disease-associated structures), and tailored treatment regimens. monoclonal antibodies (mAbs) present an The fundamental challenge of anticancer innovative class of biopharmaceuticals with drug treatment is to effectively eliminate can- increasing clinical importance. However, in cer cells in an individual patient using a treat- some cases only a certain fraction of patients ment protocol with dosing regimens that are benefits from these “targeted therapies” [3]. In tolerated. Most classical cytotoxic anticancer addition, in therapeutic use the outcome with agents do not distinguish between healthy and respect to efficacy and toxicity (incl. immuno- cancer cells and thus inhibit essential func- genicity) has been reported to be considerably tions in both healthy and malignant cell popu- variable suggesting mechanisms inherent to lations. A new generation of anticancer drugs patient (system) characteristics. has been designed to interfere with specific For two mAbs targeting the epidermal molecular targets identified as playing a criti- growth factor receptor (EGFR) system, cetux- cal role in tumor growth and progression. In imab and panitumumab, metastatic colorectal both cases, elucidation of the mechanisms and tumor patients bearing the mutated K-ras gene pathways at the molecular, cellular, tissue, or- did not benefit (progression-free and overall gan and organism level is crucial. There is an survival) from the drug treatment [4]. The urgent need for markers that indicate success, mAb trastuzumab has been approved in pa- failure or toxicity prior to or at an early stage tients with metastatic breast cancer but being of the anticancer treatment (“biomarkers”). indicated only in those ~ 25 – 30% of patients with relative overexpression of the HER2/neu Correspondence to receptor on the cell surface of the tumor cell. Prof. Dr. Charlotte Kloft Department of Clinical Methodology and concepts For these mAbs, the biomarkers K-ras and Pharmacy and Biochem- HER2 represent the status of the patient or the istry, Freie Universitaet Pharmacometrics represents an emerging state of disease. In their static use as ‘exclu- Berlin, Kelchstraße 31, science based on a transdisciplinary approach sion’ criterion, these biomarkers serve as a 12169 Berlin, Germany charlotte.kloft@ bridging concepts of biology, pharmacology, diagnostic tool and prevent useless or even fu-berlin.de clinical pharmacy and pharmacology, medi- harmful treatments for patients. In that, bio- Kloft 90 markers nowadays present an enormous value 2. key pathway markers in stratified (not personalized) medicine. 3. drug concentrations Additionally, the pharmacokinetics (PK) of 4. biomarker/PD data mAbs is unique compared to small molecule 5. pharmacogenetic data drugs: their binding/elimination characteristics comprise multiple pathways, in particular the 6. clinical data often observed parallel linear and nonlinear What is lacking today is not only the elimination pathways [5]. Furthermore, PK “network of experimental, in silico and clini- is also influenced by the pharmacodynam- cal data” but also the “network of method- ics (PD) and vice versa in terms of binding to ological expertise”. the target (“target-mediated drug disposition”, TMDD). Moreover, intracellular downstream In future, effective integration of both processes of the drug-receptor complex should disciplines – pharmacometrics and systems be taken into account [6]. Several PK and PD biology as systems pharmacology – might parameters have been reported to be related to not only foster research on pharmacokinet- patient demographic characteristics, e.g., the ics, pharmacodynamics and biomarkers for different clearances to body size [5]. However, disease and treatment outcome. Combining systematic and mechanistic investigations are approaches of cross-disciplinary interaction still sparse but highly warranted. (e.g. preclinical and clinical oncology) re- quiring open mindness and communication might also streamline decision making in the Perspectives two important fields: Both disciplines – pharmacometrics and (1) in drug development (known as: mod- systems biology – are rather young, have in- el-based drug development) and ternationally gained attractiveness but have up- (2) in patient care to increase the benefit/ to-now often been considered only separately. risk ratio of the therapeutic use in the indi- Especially in oncology, it is time to revisit the vidual tumor patient (proposed to be named current approaches of data generation and of as: model-based patient care). data analysis incl. modeling & simulation con- cepts. One objective in joint efforts could result in a thorough understanding of the underlying mechanisms of drug disposition, target bind- References ing, drug-target complex signal transduction, [1] Barrett JS, Fossler MJ, Cadieu KD, Gastonguay e.g. inside the cell in various sub-cellular com- MR. Pharmacometrics: a multidisciplinary field to partments and target dynamics, as well as the facilitate critical thinking in drug development and translational research settings. J Clin Pharma- impact of patient, treatment and study charac- col. 2008; 48: 632-649. teristics. To one end, biomarkers might extend doi:10.1177/0091270008315318 PubMed [2] Alberghina L, Westerhoff H. Systems Biology: their role from being used today in stratified Definitions and Perspectives. Topics in Current medicine based on target (non)expression to Genetics. 13. Berlin: Springer-Verlag, 2005. [3] Kuester K. Kloft C. Pharmacokinetics of mono- serving in future as mechanism-driven, predic- clonal antibodies In: B. Meibohm (Ed.), Wiley- tive biomarkers for personalized medicine. VCH Verlag, Weinheim, 2006; 45-91. [4] Karapetis CS, Khambata-Ford S, Jonker DJ, As a prerequisite, the strengths of basic O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, and applied research groups have to be com- Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalc- bined by exploiting the wealth of berg JR. K-ras mutations and benefit from cetux- imab in advanced colorectal cancer. N Engl J – Multiple levels of data, namely Med. 2008; 359: 1757-1765. doi:10.1056/NEJ- 1. molecular level Moa0804385 PubMed 2. cell level [5] Kuester K, Kovar A, Lüpfert C, Brockhaus B, Kloft C. Refinement of the population pharmaco- 3. tissue level kinetic model for the monoclonal antibody matu- zumab: external model evaluation and simula- 4. organ level tions. Clin Pharmacokinet. 2009; 48: 477-487. 5. patient level (→ society) doi:10.2165/11313400-000000000-00000 PubMed and [6] Krippendorff BF, Kuester K, Kloft C, Huisinga W. Nonlinear pharmacokinetics of therapeutic pro- – Multiple types of data (quantitative, over teins resulting from receptor mediated endocyto- time), namely sis. J Pharmacokinet Pharmacodyn. 2009; 36: 239-260. doi:10.1007/s10928-009-9120-1 1. target expression PubMed.

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    2 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us